Waters launches LC platform-neutral bioseparations system

By Staff Reporter

- Last updated on GMT

Related tags: High performance liquid chromatography

Image c/o Waters
Image c/o Waters
Waters Corporation says its latest bioseparations system can drive cost-savings through reduced solvent volumes and decreased run times.

Aimed at late stage development, QC, and routine analysis pharmaceutical customers, processing tools maker Waters has launched the latest system in its Acquity Arc bioseparation analytical range: the Acquity Arc Bio system.

The system is based on Water’s Arc Multi-flow path technology, which director of Product Marketing Chromatography Systems Eric Grumbach said enables ease of transfer.

“Arc Multi-flow path technology enables the system to have a selectable dwell volume that delivers compatibility of both HPLC and UHPLC methods, significantly simplifying method transfer,”​ he told this publication.

Also known as delay volume, dwell volume is the volume inherent of the system components that result on how quickly the product once mixed will travel to the head of the separation columns. It affects the mixing behaviour of the solvents and is handled differently by different types of liquid chromatography (LC) systems.

According to Grumbach, matching the dwell volume of two disparate systems can help successfully transfer methods from one system to another, something the Arc Multi-Flowpath technology allows automatically.

“As for simplifying method development, the Acquity Arc Bio System, when paired with modern 2.5 µm UHPLC [ultra high performance liquid chromatography] columns, enables methods to be developed 4 fold faster than traditional 5 µm HPLC [high-performance liquid chromatography] columns,”​ he added.

“The combined ability to transition from HPLC to UHPLC, reduce solvent volumes, and decrease run times will result in significant efficiency improvements and cost savings.”

Related news

Related products

show more

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 21-May-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

High-Density Vero Cell Perfusion Culture

High-Density Vero Cell Perfusion Culture

Eppendorf for Bioprocess – Solutions that grow with you | 01-May-2018 | Application Note

Viral diseases like rabies, rotavirus and influenza are causing many deaths worldwide, resulting in a strong demand for more productive manufacturing techniques...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Featured eBook: Complex Protein Production

Featured eBook: Complex Protein Production

Catalent Pharma Solutions | 06-Mar-2018 | Technical / White Paper

Download the eBook written by Catalent experts to learn about innovative products and techniques for scale-up of complex biologics, get optimal cell culture...

Related suppliers